ERT Introduces Centralized DLCO Services for Respiratory Trials
Centralization reduces data variability, improves trial efficiencies
PHILADELPHIA, PA â ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today introduced its Centralized Services for assessing diffusing capacity of the lungs for carbon monoxide (DLCO) data in respiratory clinical trials. DLCO is valuable for determining clinical endpoints in Asthma, COPD, Idiopathic Pulmonary Fibrosis, and Cystic Fibrosis studies, as well as in clinical research for inhaled drugs or compounds impacting diffusing capacity. Repeated DLCO measurements aid in determining the efficacy or safety of drugs that are not obtainable by standard spirometry or imaging. Centralized DLCO Services integrates the EasyOne Pro device from ndd into ERT’s EXPERT Central private cloud platform for near real-time evaluation, notifications, expert overread, data reconciliation, and reporting. The solution includes ERT’s well recognized project assurance, data management, and training programs that enable investigative sites to optimize DLCO and spirometry collection. “Although DLCO tests are typically convenient and easy for patients to perform, independent studies have shown that DLCO measurements of the same patient in different labs can vary as much as 50%,” said Achim Schülke, Executive Vice President, Respiratory Solutions at ERT. “By centralizing DLCO collection with ERT’s solution, clinical trial sponsors benefit from higher data quality, reduced site burden, improved study oversight, and shortened timelines.” Clinical researchers can learn more about ERT’s Centralized DLCO Services in booth #509 at the Drug Information Association (DIA) Annual Meeting in Philadelphia, June 27-29 or at
www.ert.com/respiratory
.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) â which includes patient-, clinician-, observer- and performance-reported outcomes â and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
